- Home
- DRIO vs FGEN Comparison
DRIO vs FGEN Comparison
Compare DRIO & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRIO
- FGEN
- Stock Information
- Founded
- DRIO 2011
- FGEN 1993
- Country
- DRIO United States
- FGEN United States
- Employees
- DRIO N/A
- FGEN N/A
- Industry
- DRIO Medical/Dental Instruments
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- DRIO Health Care
- FGEN Health Care
- Exchange
- DRIO Nasdaq
- FGEN Nasdaq
- Market Cap
- DRIO 27.9M
- FGEN 33.5M
- IPO Year
- DRIO N/A
- FGEN 2014
- Fundamental
- Price
- DRIO $0.59
- FGEN $0.30
- Analyst Decision
- DRIO Strong Buy
- FGEN Strong Buy
- Analyst Count
- DRIO 1
- FGEN 1
- Target Price
- DRIO $2.00
- FGEN $10.00
- AVG Volume (30 Days)
- DRIO 293.8K
- FGEN 1.6M
- Earning Date
- DRIO 05-14-2025
- FGEN 05-05-2025
- Dividend Yield
- DRIO N/A
- FGEN N/A
- EPS Growth
- DRIO N/A
- FGEN N/A
- EPS
- DRIO N/A
- FGEN N/A
- Revenue
- DRIO $27,040,000.00
- FGEN $29,621,000.00
- Revenue This Year
- DRIO $22.40
- FGEN $544.98
- Revenue Next Year
- DRIO $21.41
- FGEN $9.45
- P/E Ratio
- DRIO N/A
- FGEN N/A
- Revenue Growth
- DRIO 32.86
- FGEN N/A
- 52 Week Low
- DRIO $0.56
- FGEN $0.18
- 52 Week High
- DRIO $1.93
- FGEN $2.33
- Technical
- Relative Strength Index (RSI)
- DRIO 38.41
- FGEN 38.86
- Support Level
- DRIO $0.62
- FGEN $0.30
- Resistance Level
- DRIO $0.74
- FGEN $0.38
- Average True Range (ATR)
- DRIO 0.05
- FGEN 0.05
- MACD
- DRIO -0.01
- FGEN -0.00
- Stochastic Oscillator
- DRIO 15.20
- FGEN 16.30
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.